Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study determines the Maximum Tolerable Dose (MTD) by maximum BSA percentage treated and
evaluates efficacy of various concentrations of AMTX-100 CF versus placebo (vehicle).
The study has two parts:
Phase I (Part 1):
Approximately Twenty five (25) subjects with various treatable Body Surface Area (BSA)
involvement of Mild to Moderate Atopic Dermatitis will be enrolled in the study and treated
with 1.1% w/w AMTX-100 CF.
Phase II (Part 2):
Approximately One Hundred Twenty (120) subjects with Mild to Moderate Atopic Dermatitis with
various treatable BSA involvement of Mild to Moderate Atopic Dermatitis will be randomized to
be treated with different concentrations of AMTX-100 CF (low concentration (0.11% w/w),
medium concentration (0.33% w/w) and high concentration (1.1% w/w)) or Vehicle (Placebo) in
the study.